Cardiovascular Endocrinology & Metabolism最新文献_第10页

Cardioprotective diabetes drugs: what cardiologists need to know. 保护心脏的糖尿病药物:心脏病专家需要知道的。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2019-11-13 eCollection Date: 2019-12-01 DOI: 10.1097/XCE.0000000000000181

Jenifer M Brown, Brendan M Everett

{"title":"Cardioprotective diabetes drugs: what cardiologists need to know.","authors":"Jenifer M Brown, Brendan M Everett","doi":"10.1097/XCE.0000000000000181","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000181","url":null,"abstract":"In patients with diabetes, where cardiovascular morbidity is highly prevalent, recent cardiovascular outcomes trials have identified therapies in the modern glucagon-like peptide 1 receptor agonist (GLP-1RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) classes that significantly reduce cardiovascular events. A number of drugs in both classes have demonstrated reductions in the risk of the composite outcome of major adverse cardiovascular events (myocardial infarction, stroke, and cardiovascular death). In addition, SGLT2i drugs have a substantial impact on hospitalization for heart failure. Because GLP-1RA and SGLT2i are effective in reducing cardiovascular events, independent of their effects on blood glucose, cardiologists should be familiar with how to use them. This review outlines the evidence of cardiovascular benefit for current GLP-1RA and SGLT2i drugs, practical information for prescribing them, and putative mechanisms, so that these therapies can be incorporated along with antihypertensives, statins, and antiplatelet therapies into the routine care of patients.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"8 4","pages":"96-105"},"PeriodicalIF":2.3,"publicationDate":"2019-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000181","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37546498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Estimation of apolipoprotein A in early onset ST-segment elevation myocardial infarction. 早发性st段抬高型心肌梗死载脂蛋白A的测定。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2019-11-13 eCollection Date: 2019-12-01 DOI: 10.1097/XCE.0000000000000183

Ameen Mosa Mohammad, Ahmed Hasan Yousif, Bayar Ahmed Qasim, Joma Aziz Joma, Saad Younis Saeed

{"title":"Estimation of apolipoprotein A in early onset ST-segment elevation myocardial infarction.","authors":"Ameen Mosa Mohammad, Ahmed Hasan Yousif, Bayar Ahmed Qasim, Joma Aziz Joma, Saad Younis Saeed","doi":"10.1097/XCE.0000000000000183","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000183","url":null,"abstract":"Aims: The role of apolipoprotein A in early onset ST-segment elevation myocardial infarction is not clear. This study sought to assess the apolipoprotein A in cohort of patients diagnosed with early onset acute ST-segment elevation myocardial infarction and to corelate it with major traditional cardiovascular risk factors.Methods: A total of 50 such patients and 40 age and sex-matched healthy controls, both aged less than 50 years with their baseline demographic, clinical characteristics and cardiovascular risk factors were studied. Apolipoprotein A was estimated for all enrollees.Results: The mean age of cases was 43.37 ± 5.85 years. The levels of apolipoprotein A among cases were not significantly lower compared to controls (P = 0.52). They were lower among the male, current smokers and the dyslipidemia (P's < 0.05). Considering the apolipoprotein A as the dependent factor, the early onset ST-segment elevation myocardial infarction was associated significantly with the male and the dyslipidemia in linear regression (P < 0.001 and 0.030), respectively.Conclusion: Lower levels of apolipoprotein A are significantly related to conventional risk factors in early onset ST-segment elevation myocardial infarction. This apolipoprotein A that particularly develops in young patients with clustering of traditional cardiovascular risk factors should be targeted. Further studies are warranted to determine the diagnostic and prognostic indicators of this apolipoprotein in ST-segment elevation myocardial infarction.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"8 4","pages":"106-108"},"PeriodicalIF":2.3,"publicationDate":"2019-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000183","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37546499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addressing the impact of type 2 diabetes in ageing populations: the launch of the 2019 Endocrine Society Task Force Guideline. 应对2型糖尿病对老龄化人群的影响：发布2019年内分泌学会工作组指南。

IF 1.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2019-09-10 eCollection Date: 2019-09-01 DOI: 10.1097/XCE.0000000000000177

A J Sinclair

引用次数: 0

Association of lipid peroxidation and interleukin-6 with carotid atherosclerosis in type 2 diabetes. 脂质过氧化和白细胞介素-6与2型糖尿病颈动脉粥样硬化的关系。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2019-09-01 DOI: 10.1097/XCE.0000000000000175

Hesham Alharby, Talaat Abdelati, M. Rizk, E. Youssef, K. Moghazy, N. Gaber, Saeed Yafei

{"title":"Association of lipid peroxidation and interleukin-6 with carotid atherosclerosis in type 2 diabetes.","authors":"Hesham Alharby, Talaat Abdelati, M. Rizk, E. Youssef, K. Moghazy, N. Gaber, Saeed Yafei","doi":"10.1097/XCE.0000000000000175","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000175","url":null,"abstract":"Enhanced lipid peroxidation and elevated interleukin-6 levels are common in type 2 diabetes mellitus patients. Atherosclerotic vascular complications greatly contribute to morbidity and mortality in diabetes. The aim of this study was to assess the relation of lipid peroxidation and interleukin-6 with carotid atherosclerosis in type 2 diabetes mellitus.\u0000\u0000\u0000Methods\u0000This cross-sectional study included 90 type 2 diabetes mellitus male patients with age ≥ 40 years and 30 healthy male subjects matched for age. All of them were subjected to measuring of 8-iso prostaglandin F2α as a marker of lipid peroxidation, interleukin-6 and carotid intima media thickness as a marker of carotid atherosclerosis.\u0000\u0000\u0000Results\u0000Both 8-iso prostaglandin F2α and interleukin-6 were found to have significant positive correlation with carotid intima media thickness (P < 0.001) and both were found to be significant predictors of the presence of subclinical carotid atherosclerosis in multiple regression analysis.\u0000\u0000\u0000Conclusion\u0000Lipid peroxidation and interleukin-6 may play an important role in atherogenesis in type 2 diabetes mellitus and limiting their effects may reduce atherosclerotic vascular complications in type 2 diabetes mellitus.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000175","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48060683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Association of neutrophil-gelatinase-associated lipocalin with microvascular complications in patients with type 2 diabetes: a cross-sectional study. 中性粒细胞-明胶酶相关脂钙蛋白与2型糖尿病患者微血管并发症的关联:一项横断研究

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2019-09-01 DOI: 10.1097/XCE.0000000000000180

Erhan Aslanhan, Dávid Ojalvo, Ekmek Burak Özsenel, Sema Uçak Basat, F. Borlu

{"title":"Association of neutrophil-gelatinase-associated lipocalin with microvascular complications in patients with type 2 diabetes: a cross-sectional study.","authors":"Erhan Aslanhan, Dávid Ojalvo, Ekmek Burak Özsenel, Sema Uçak Basat, F. Borlu","doi":"10.1097/XCE.0000000000000180","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000180","url":null,"abstract":"Diabetic nephropathy and diabetic retinopathy are serious microvascular complications of diabetes mellitus. Recent studies have demonstrated that neutrophil-gelatinase-associated lipocalin (NGAL) may be accompanied by these complications during and before the appearance of microalbuminuria. In this study, we set out to research the role of NGAL in patients with diabetic nephropathy and diabetic retinopathy.\u0000\u0000\u0000Material and methods\u0000Eighty-two patients with type 2 diabetes were enrolled in our study. Urinary microalbumine and NGAL levels were measured in urine samples over 24 hours. We also studied NGAL levels in serum. All patients went through an ophthalmologic examination. The results were evaluated based on the presence of microalbuminuria and retinopathy.\u0000\u0000\u0000Results\u0000There were no significant differences in serum and urine NGAL levels between normoalbuminuric (n = 66) and microalbuminuric (n = 16) patients. We also did not find any significant difference in patients with retinopathy (n = 16) or without retinopathy (n = 66).\u0000\u0000\u0000Conclusion\u0000There are controversial findings about the role of NGAL in diabetic patients in medical literature. Standard values of urine and serum NGAL levels have yet to be determined. Our study suggests that NGAL is not a useful marker to differentiate microalbuminuric patients from normoalbuminuric subjects. We also did not find a relationship between NGAL levels and the presence of retinopathy. Additional studies with larger sample sizes will be required to confirm or refute these findings.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000180","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46253365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Relative fat mass is a better predictor of dyslipidemia and metabolic syndrome than body mass index. 相对脂肪量比体重指数更能预测血脂异常和代谢综合征。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2019-09-01 DOI: 10.1097/XCE.0000000000000176

O. Kobo, R. Leiba, O. Avizohar, A. Karban

{"title":"Relative fat mass is a better predictor of dyslipidemia and metabolic syndrome than body mass index.","authors":"O. Kobo, R. Leiba, O. Avizohar, A. Karban","doi":"10.1097/XCE.0000000000000176","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000176","url":null,"abstract":"Relative fat mass (RFM) had been recently developed. We aimed to examine RFM predictability to various cardiometabolic risk factors, compared to BMI.\u0000\u0000\u0000Methods\u0000Observational, cohort study, among patients who visited the Rambam Periodic Examinations Institute (RPEI). We compared the correlation of BMI and RFM to hypertension, impaired fasting glucose, high LDL, low HDL and metabolic syndrome, by gender.\u0000\u0000\u0000Results\u0000During study years, 20 167 patients visited the RPEI and included in the trial. Compared to BMI, RFM showed significantly better predictability (odds ratio [OR], [95% confidence interval (CI), P value]) of high LDL [1.618 (1.441-1.816, P < 0.001) vs. 0.732 (0.67-0.8, P < 0.001) in men; 1.572 (1.377-1.794, P < 0.001) vs. 0.938 (0.849-1.163, P = 0.94) in women], low HDL [2.944 (2.569-3.373, P < 0.001) vs. 2.177 (2-2.369, P < 0.001) in men, 2.947 (2.519-3.448, P < 0.001) vs. 1.9 (1.658-2.176, P < 0.001) in women], high triglycerides [4.019 (3.332-4.847, P < 0.001) vs. 1.994 (1.823-2.181, P < 0.001) in men, 3.93 (2.943-5.247, P < 0.001) vs. 2.24 (1.887-2.62, P < 0.001) in women] and metabolic syndrome [7.479, (4.876-11.47, P < 0.001) vs. 3.263 (2.944-3.616, P < 0.001) in men, 16.247 (8.348-31.619, P < 0.001) vs. 5.995 (5.099-7.048, P < 0.001) in women]. There was no significant difference in the predictability of BMI and RFM to hypertension and diabetes mellitus.\u0000\u0000\u0000Conclusion\u0000RFM provides high predictability for dyslipidemias and metabolic syndrome.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000176","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43062544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 21

27th Annual Meeting of the European Group for the study of Insulin Resistance, Lisbon, Portugal, 8-9th May 2019. 欧洲胰岛素抵抗研究小组第27届年会，葡萄牙里斯本，2019年5月8日至9日。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2019-09-01 DOI: 10.1097/XCE.0000000000000179

C. Bonner, John Jones, M. Paula Macedo, A. Gastaldelli

引用次数: 0

Elizabeth Barrett-Connor (1935-2019): an appreciation. 伊丽莎白·巴雷特-康纳(Elizabeth Barrett-Connor, 1935-2019):感谢。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2019-09-01 DOI: 10.1097/XCE.0000000000000182

A. Krentz

引用次数: 0

Cardiometabolic medicine: time to recognize a new clinical specialty? 心脏代谢医学：是时候承认一个新的临床专业了吗？

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2019-05-15 DOI: 10.1097/XCE.0000000000000173

A. Krentz, S. Jacob

引用次数: 7

DiRECT and indirect paths to reducing cardiovascular risk in diabetes: insights from Diabetes UK 2019. 降低糖尿病心血管风险的直接和间接途径:2019年英国糖尿病协会的见解。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2019-05-15 DOI: 10.1097/XCE.0000000000000174

A. Krentz

引用次数: 1